A Phase I/II, Open-label, Dose-escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) Administered Orally to Subjects with Locally Advanced or Metastatic Melanoma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs RAF 265 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 24 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Oct 2013 Planned end date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov.